Skip to content

Lactoferrin Versus Iron Supplement in Irondeficiency Anemia and Weight Loss in Obese Children

The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04014855
Enrollment
50
Registered
2019-07-10
Start date
2018-10-01
Completion date
2019-07-01
Last updated
2019-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Childhood

Brief summary

The effect of lactoferrin versus iron supplement in treating iron deficiency anemia and helping weight loss in obese school age children

Detailed description

Comparing iron versus lactoferrin as regard iron defiency anemia and weight loss in obese children

Interventions

in iron deficiency anemia

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* 1\. children age will be between 6 -12 years old. 2. Presence of iron deficiency anemia, it will be diagnosed by * CBC \>\> Hemoglobin level concentration below 11.5 g/dl. * level of serum iron is below 30 µmol/l, * level of ferritin is below 15 µg/dl * Total iron binding capacity is more 480 µg/dlL. 3. children should be stable and free from chronic disease. 4. Body Mass index (BMI) should be ≥the 95th percentile for children and teens of the same age and sex. 5\. there is not history of iron supplements in the 3 months before treatment.

Exclusion criteria

1. Father/mother refuses to participate in the study. 2. Hospitalized patient. 3. Non-anemic patient. 4. Patients receiving iron supplements 3 months before enrollment. 5. Patients with chronic diseases. 6. personal or family history of allergy to cow's milk or infant formula, eczema, moderate-to-severe allergic rhinitis or asthma, or milk intolerance. 7. severe anemia as Hemoglobin level concentration below 7 g/dl.

Design outcomes

Primary

MeasureTime frameDescription
iron deficiency anemia3 monthsCBC and iron profile

Secondary

MeasureTime frameDescription
weight3 monthsWeight and body copmositiin

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026